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background
 
The standard initial treatment of hemodynamically stable patients with pulmonary em-
bolism is intravenous unfractionated heparin, requiring laboratory monitoring and hos-
pitalization.
 
methods
 
We conducted a randomized, open-label trial involving 2213 patients with acute symp-
tomatic pulmonary embolism to compare the efficacy and safety of the synthetic anti-
thrombotic agent fondaparinux with those of unfractionated heparin and to document
noninferiority in terms of efficacy. Patients received either fondaparinux (5.0, 7.5, or
10.0 mg in patients weighing less than 50, 50 to 100, or more than 100 kg, respectively)
subcutaneously once daily or a continuous intravenous infusion of unfractionated
heparin (ratio of the activated partial-thromboplastin time to a control value, 1.5 to
2.5), both given for at least five days and until the use of vitamin K antagonists resulted
in an international normalized ratio above 2.0. The primary efficacy outcome was the
three-month incidence of the composite end point of symptomatic, recurrent pulmo-
nary embolism (nonfatal or fatal) and new or recurrent deep-vein thrombosis.
 
results
 
Forty-two of the 1103 patients randomly assigned to receive fondaparinux (3.8 percent)
had recurrent thromboembolic events, as compared with 56 of the 1110 patients ran-
domly assigned to receive unfractionated heparin (5.0 percent), for an absolute differ-
ence of ¡1.2 percent in favor of fondaparinux (95 percent confidence interval, ¡3.0 to
0.5). Major bleeding occurred in 1.3 percent of the patients treated with fondaparinux
and 1.1 percent of those treated with unfractionated heparin. Mortality rates at three
months were similar in the two groups. Of the patients in the fondaparinux group,
14.5 percent received the drug in part on an outpatient basis.
 
conclusions
 
Once-daily, subcutaneous administration of fondaparinux without monitoring is at least
as effective and is as safe as adjusted-dose, intravenous administration of unfractionat-
ed heparin in the initial treatment of hemodynamically stable patients with pulmonary
embolism.
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ulmonary embolism is a frequent
 
and often life-threatening event that con-
tributes to 5 to 10 percent of deaths among
hospitalized patients.
 
1
 
 The goals of antithrombotic
therapy for this disease are to minimize early mor-
bidity and mortality and to prevent recurrence with-
out provoking excessive bleeding. In hemodynam-
ically stable patients, unfractionated heparin is
effective and remains the reference therapy for ini-
tial anticoagulation.
 
1-4
 
 Because unfractionated hep-
arin requires continuous intravenous infusion with
regular laboratory monitoring and dose titration,
patients remain hospitalized even when their clini-
cal condition permits discharge. A less complex and
resource-intensive but equally efficacious and safe
treatment, allowing earlier discharge, would be de-
sirable.
Low-molecular-weight heparins have replaced
unfractionated heparin for the treatment of most
patients with deep-vein thrombosis,
 
3
 
 but in patients
with symptomatic acute pulmonary embolism they
have been less extensively evaluated.
 
5-7
 
 As a result,
use of low-molecular-weight heparins for this indi-
cation varies, and in many countries they have not
been approved by regulatory authorities for the ini-
tial treatment of patients with pulmonary embolism.
Fondaparinux is a synthetic antithrombotic agent
with specific anti–factor Xa activity. Its pharmacoki-
netic properties allow for a simple, fixed-dose, once-
daily regimen of subcutaneous injection, without
the need for monitoring.
 
8
 
 In a dose-ranging trial in-
volving patients with symptomatic proximal deep-
vein thrombosis, 7.5 mg of fondaparinux appeared
to have efficacy and safety similar to those of a low-
molecular-weight heparin (dalteparin).
 
9
 
Given the practical advantages of a simple fonda-
parinux regimen, this study was designed to deter-
mine whether fixed-dose, once-daily, subcutaneous
administration of fondaparinux is at least as effec-
tive as unfractionated heparin for the initial treat-
ment of symptomatic pulmonary embolism. This
randomized trial, with blinded adjudication of out-
come events, was conducted on an open-label ba-
sis, permitting early discharge in the fondaparinux
group.
 
patients
 
Consecutive patients 18 years of age or older who
presented with acute symptomatic pulmonary em-
bolism and who required antithrombotic therapy
were potentially eligible for the study. Diagnostic
criteria were an intraluminal filling defect on spiral
computed tomography (CT) or pulmonary angiog-
raphy, a high-probability ventilation–perfusion lung
scan, or a nondiagnostic lung scan with documen-
tation of deep-vein thrombosis either by compres-
sion ultrasonography or by venography.
 
5
 
Patients were ineligible for the study if they had
received therapeutic doses of low-molecular-weight
heparin or oral anticoagulants for more than 24
hours; if they required thrombolysis, embolectomy,
or a vena cava filter; or if anticoagulant therapy was
contraindicated — for example, because of active
bleeding or thrombocytopenia (a platelet count be-
low 100,000 per cubic millimeter). Patients were
also ineligible if they had a serum creatinine level
above 2.0 mg per deciliter (177 µmol per liter) or
uncontrolled hypertension (systolic blood pressure
greater than 180 mm Hg or diastolic blood pressure
greater than 110 mm Hg); if they were pregnant; or
if a physician had estimated the life expectancy to be
less than three months.
After written informed consent had been ob-
tained, randomization was performed at a central
location with the use of a computerized, interactive
voice-response system that recorded information
about the patient before his or her treatment assign-
ment. The protocol was approved by the institution-
al review board at each of the study centers. The
study was monitored by an independent data and
safety monitoring board. The data were collected
and held by the two sponsors, NV Organon and
Sanofi-Synthélabo. The statistical-analysis plan was
approved by the steering committee, which also
checked the final analysis.
 
treatment regimens
 
The patients assigned to fondaparinux (Arixtra, NV
Organon and Sanofi-Synthélabo) received a single
daily subcutaneous injection of 5.0 mg (if their
body weight was less than 50 kg), 7.5 mg (if their
body weight was 50 to 100 kg), or 10.0 mg (if
their body weight was greater than 100 kg). The pa-
tients assigned to unfractionated heparin received
an initial intravenous bolus of at least 5000 IU, fol-
lowed by at least 1250 IU per hour, administered
as a continuous intravenous infusion. The infusion
dose was adjusted to maintain the activated partial-
thromboplastin time at 1.5 to 2.5 times a control
value.
 
10,11
 
 The activated partial-thromboplastin
time was measured approximately six hours after
the start of heparin treatment, about six hours after
p
methods
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each measurement of the activated partial-throm-
boplastin time that was subtherapeutic or supra-
therapeutic, and otherwise daily. Heparin was pro-
vided by American Pharmaceutical Partners for all
centers except those in France, where it was sup-
plied by Laboratoires Choay.
In both groups, treatment with a vitamin K an-
tagonist was begun as soon as possible and within
72 hours after initiation of the study treatment. Ini-
tially, the prothrombin time was measured at least
every other day, and the dose of vitamin K antagonist
was adjusted to maintain the international normal-
ized ratio (INR) at a value between 2.0 and 3.0. Ad-
ministration of heparin or fondaparinux was con-
tinued for at least five days and until the INR had
been greater than 2.0 for two consecutive days.
Treatment with a vitamin K antagonist was contin-
ued for three months, and the INR was determined
at least once per month.
 
surveillance and follow-up
 
All the patients were contacted daily during the ini-
tial treatment period and at one and three months
after the start of the study. At each contact, the pa-
tient was evaluated for symptoms and signs of re-
current venous thromboembolism and bleeding. All
the patients were informed about the symptoms and
signs of recurrent pulmonary embolism and deep-
vein thrombosis and about the potential for bleed-
ing. They were instructed to report to the study cen-
ter immediately if any of these conditions occurred.
The protocol required objective testing in cases of
suspected recurrent pulmonary embolism or deep-
vein thrombosis.
 
assessment of outcomes
 
The primary efficacy outcome was symptomatic re-
current venous thromboembolism during the three-
month study period. Symptomatic recurrent venous
thromboembolism was considered to have occurred
if recurrent pulmonary embolism or deep-vein
thrombosis was documented objectively or if there
was a death in which pulmonary embolism was a
contributing cause or could not be ruled out. In the
absence of objective test results that adequately con-
firmed or ruled out recurrent venous thromboem-
bolism, the diagnosis was accepted if the condition
was managed with therapeutic dosages of low-
molecular-weight heparin for more than two days,
thrombolysis, a vena caval filter, or thrombectomy.
The objective criterion for the diagnosis of recur-
rent pulmonary embolism was a new intraluminal
filling defect on spiral CT or pulmonary angiogra-
phy; cutoff of contrast material in a vessel more than
2.5 mm in diameter on pulmonary angiography; a
new perfusion defect involving at least 75 percent of
a segment, with corresponding normal ventilation
(i.e., a high-probability lung scan); a new nondiag-
nostic lung scan accompanied by documentation
of deep-vein thrombosis by ultrasonography or ve-
nography; or confirmation of a new pulmonary em-
bolism at autopsy.
 
5,12
 
 The objective criterion for the
diagnosis of new deep-vein thrombosis was a new,
noncompressible venous segment or a substantial
increase (4 mm or more) in the diameter of the
thrombus during full compression in a previously
abnormal segment on ultrasonography or a new in-
traluminal filling defect on venography.
 
13,14
 
The main safety outcomes were major bleeding
during the initial treatment period and death during
the three-month study period. Bleeding was consid-
ered major if it was clinically overt and associated
with a decrease of 2 g per deciliter or more in the he-
moglobin level, led to the transfusion of 2 or more
units of red cells or whole blood, was retroperito-
neal or intracranial, occurred in a critical organ, or
contributed to death. Bleeding episodes that were
clinically relevant but did not qualify as major (e.g.,
epistaxis that required intervention, formation of a
large hematoma visible on the skin, or spontaneous
macroscopic hematuria) were an additional safety
outcome and were classified as clinically relevant
nonmajor bleeding. All other hemorrhages were
categorized as trivial. The cause of death was classi-
fied as pulmonary embolism, bleeding, cancer, or
another established diagnosis or was considered to
be unexplained. All suspected outcome events were
reviewed and classified by a central adjudication
committee whose members were unaware of the
treatment assignments.
Platelet counts were assessed at base line, on
day 4, and at the end of initial treatment. Antiplate-
let antibodies were measured at base line and at the
end of initial treatment and also were measured if
heparin-induced thrombocytopenia was suspected
because the platelet count was confirmed on retest-
ing to be below 100,000 per cubic millimeter or to
have decreased by more than 40 percent from the
base line count.
 
15
 
statistical analysis
 
We assumed a 5 percent incidence of the primary ef-
ficacy outcome in the unfractionated-heparin group
and hypothesized that fondaparinux would be as
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 28, 2017. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
349;18
 
www.nejm.org october 
 
30
 
, 
 
2003
 
The
 
 new england journal 
 
of
 
 medicine
 
1698
 
effective as unfractionated heparin.
 
3
 
 Studies in
patients with pulmonary embolism or deep-vein
thrombosis who received no treatment or inade-
quate treatment have found recurrence rates of ap-
proximately 20 percent.
 
2,16,17
 
 On the basis of pre-
vious studies, we chose a fixed noninferiority margin
of 3.5 percent for the absolute difference between
the two treatment groups in the rates of venous
thromboembolism.
 
4,5,7,12,16,17
 
 From these assump-
tions, we calculated that a study with 1100 patients
per group would have 95 percent power, with a one-
sided type I error of 0.025, to reject the hypothesis
that the rate of recurrence with fondaparinux would
be 3.5 percent higher than that with unfractionated
heparin.
The primary efficacy analysis was based on the
incidence of symptomatic recurrent venous throm-
boembolism during the entire three-month study
period. Analyses of bleeding events included events
during the initial treatment period plus three, four,
or nine days, according to the creatinine clearance
(more than 50, 30 to 50, or less than 30 ml per min-
ute, respectively).
 
18
 
 Efficacy analyses were based on
data from all the patients who had been randomly
assigned to a study group, whereas safety analyses
were based on data from all the patients who actu-
ally received treatment. The 95 percent confidence
interval for the absolute difference between the
treatment groups in the rates of outcomes were
calculated with use of the normal approximation.
The steering committee had the final responsi-
bility for the study protocol, statistical analysis plan,
progress of the study and analysis, and reporting of
the data.
 
patients and base-line characteristics
 
Between May 2000 and March 2002, 5993 patients
with pulmonary embolism were screened in the 235
participating centers. Of these patients, 2948 (49
percent) were ineligible because they met one or
more of the predefined exclusion criteria. The most
common reasons for exclusion were the use of ther-
apeutic anticoagulation for more than 24 hours
(1237 patients), contraindications to anticoagulant
therapy (470), a life expectancy of less than three
months (205), and the use of thrombolytic therapy
or a vena cava filter (128). In addition, 832 patients
chose not to participate.
In total, 2213 patients were randomly assigned
to receive either fondaparinux (1103) or unfraction-
ated heparin (1110). The base-line characteristics of
the patients in the two treatment groups were sim-
ilar (Table 1). Follow-up with respect to the primary
efficacy outcome was incomplete for six of the pa-
tients assigned to the fondaparinux group (0.5 per-
cent) and seven of those assigned to the unfraction-
ated-heparin group (0.6 percent), either because of
withdrawal of informed consent (six patients) or
loss to follow-up (seven).
results
 
* Plus–minus values are means ±SD. Because of rounding, not all percentages 
total 100.
† Information on sex was missing for one patient in the fondaparinux group.
‡ Information on weight was missing for four patients in the fondaparinux 
group and one patient in the unfractionated-heparin group.
§ Information on creatinine clearance was missing for 27 patients in the fonda-
parinux group and 34 patients in the unfractionated-heparin group.
¶Some patients underwent more than one confirmatory diagnostic test.
¿ Active cancer was defined as cancer that had been treated within the previous 
 
six months or not cured.
 
Table 1. Demographic and Base-Line Characteristics of the Patients Randomly 
Assigned to a Study Group.*
Characteristic
Fondaparinux
(N=1103)
Unfractionated
Heparin
(N=1110)
 
Age — yr 63±16.2 62±16.7
Sex — male/female† 501/601 477/633
Body weight — no. (%)‡
<50 kg
50–100 kg
>100 kg
81±18.9
22 (2.0)
945 (86.0)
132 (12.0)
81±19.4
25 (2.3)
948 (85.5)
136 (12.3)
Creatinine clearance — no. (%)§
<30 ml/min
30–49 ml/min
50–79 ml/min
≥80 ml/min
26 (2.4)
173 (16.1)
361 (33.6)
516 (48.0)
28 (2.6)
164 (15.2)
353 (32.8)
531 (49.3)
Time between start of symptoms and start 
of study medication — days
5.1±6.3 5.7±8.3
Diagnostic method — no. (%)¶
High-probability lung scanning
Spiral computed tomography
Pulmonary angiography
Nondiagnostic lung scanning with docu-
mented deep-vein thrombosis
485 (44.0)
510 (46.2)
39 (3.5)
99 (9.0)
519 (46.8)
510 (45.9)
35 (3.2)
78 (7.0)
Concurrent deep-vein thrombosis — no. (%) 425 (38.5) 408 (36.8)
Admission to intensive care unit — no. (%) 291 (26.4) 307 (27.7)
Risk factors — no. (%)
Previous venous thromboembolism
Cancer
Active cancer¿
History of cancer
Surgery or trauma (within the previous 
3 mo)
Estrogen therapy
Known prothrombotic state
Two or more of the above risk factors
239 (21.7)
112 (10.2)
62 (5.6)
248 (22.5)
154 (14.0)
58 (5.3)
241 (21.8)
236 (21.3)
128 (11.5)
54 (4.9)
260 (23.4)
164 (14.8)
41 (3.7)
260 (23.4)
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treatment
 
Table 2 presents data on the initial treatment and
vitamin K–antagonist therapy in the 1092 patients in
each group who received treatment. The duration of
initial treatment was similar in the two groups. An
adequate anticoagulation response to unfractionat-
ed heparin (i.e., an activated partial-thromboplastin
time above the lower limit) was achieved in a high
proportion of patients.
Of the 158 patients in the fondaparinux group
(14.5 percent) who received fondaparinux in part
on an outpatient basis, 37 did so for one day, 29 for
two days, and 92 for three or more days. In both
groups, more than 90 percent of the patients had
an INR of 2.0 or more at the end of the initial treat-
ment. The intensity of treatment with vitamin K an-
tagonists was similar in the two groups.
 
recurrent venous thromboembolism
 
Of the 1103 patients assigned to receive fonda-
parinux, 140 had one or more episodes of clinically
suspected recurrent venous thromboembolism, and
the diagnosis was confirmed in 42 patients (Table
3). Among the 1110 patients assigned to receive un-
fractionated heparin, 122 had one or more episodes
of clinically suspected recurrent venous thrombo-
embolism, and the diagnosis was confirmed in 56
patients. Thus, the incidence of recurrence was 3.8
percent in the fondaparinux group and 5.0 percent
in the unfractionated-heparin group, for an absolute
difference in favor of fondaparinux of ¡1.2 percent
(95 percent confidence interval, ¡3.0 to 0.5). The
upper limit of this confidence interval indicates that
a true difference of more than 0.5 percent in favor of
unfractionated heparin was unlikely (probability of
such a difference, 2.5 percent). Hence, the nonin-
feriority of fondaparinux was clearly demonstrated.
 
bleeding complications
 
As shown in Table 3, major bleeding during initial
treatment occurred in 14 of the patients who re-
ceived fondaparinux (1.3 percent) and in 12 of those
who received unfractionated heparin (1.1 percent)
(absolute difference, 0.2 percent; 95 percent confi-
dence interval, ¡0.7 to 1.1). Bleeding contributed
to death in one patient in each treatment group.
Among the patients whose creatinine clearance was
below 30 ml per minute, major bleeding occurred
in 2 of 26 (7.7 percent) in the fondaparinux group
and in 1 of 28 (3.6 percent) in the unfractionated-
heparin group.
Major or clinically relevant nonmajor bleeding
during initial treatment occurred in 49 of the pa-
tients treated with fondaparinux (4.5 percent) and
in 69 of those treated with unfractionated heparin
(6.3 percent) (absolute difference, ¡1.8 percent; 95
percent confidence interval, ¡3.7 to 0.1). A total of
58 patients treated with fondaparinux and 67 of
those treated with unfractionated heparin were con-
sidered to have had a trivial hemorrhage. The inci-
dence of bleeding during treatment with a vitamin
K antagonist was low and was similar in the two
groups (Table 3).
 
mortality
 
During the three-month study period, 57 patients
who received fondaparinux (5.2 percent) died, as
compared with 48 who received unfractionated hep-
arin (4.4 percent) (absolute difference, 0.8 percent;
95 percent confidence interval, ¡1.0 to 2.6). In the
fondaparinux group, the causes of death were pul-
monary embolism (in 14 patients), bleeding (in 3),
cancer (in 28), and other causes (in 12). In the
 
* Plus–minus values are means ±SD. Thirteen patients randomly assigned to 
the fondaparinux group were not treated. Of the patients randomly assigned 
to receive unfractionated heparin, 16 were not treated and 2 received fonda-
parinux. INR denotes international normalized ratio.
† The lower limit was defined as 1.5 times a control value.
‡ The percentage of time spent in each INR category was calculated for each pa-
 
tient with the use of linear interpolation.
 
Table 2. Characteristics of Treatment in Each Study Group.*
Characteristic
Fondaparinux
(N=1092)
Unfractionated
Heparin
(N=1092)
 
Duration of initial treatment — days 6.5±2.2 6.9±2.2
Dose of unfractionated heparin — IU/day
Day 1
Day 2
31,193±11,370
26,124±8908
Activated partial-thromboplastin time†
Day 1
Above lower limit — no. (%)
Below lower limit — no. (%)
Data unavailable — no.
Day 2
Above lower limit — no. (%)
Below lower limit — no. (%)
Data unavailable — no.
953 (93.0)
72 (7.0)
67 
1005 (94.5)
59 (5.5)
28 
One or more days of initial treatment on an 
outpatient basis — no. (%)
158 (14.5) 0 
INR >2.0 at end of initial treatment — no. (%) 1037 (95.0) 1024 (93.8)
Mean percentage of time spent with INR 
in a given range‡
INR <2.0
INR 2.0–3.0
INR >3.0
28 
53 
19 
28 
52 
20 
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unfractionated-heparin group, the corresponding
numbers were 15, 1, 22, and 10.
 
additional observations
 
Of the 158 patients who received some fondaparinux
on an outpatient basis, 5 (3.2 percent; 95 percent
confidence interval, 1.0 to 7.2) had recurrent venous
thromboembolism, and none (95 percent confi-
dence interval, 0.0 to 2.4) had major bleeding or
died during the initial treatment.
Among patients with active cancer at the time of
enrollment, recurrent venous thromboembolism
occurred in 10 of 112 patients in the fondaparinux
group (8.9 percent) and in 22 of 128 patients in the
unfractionated-heparin group (17.2 percent). Major
bleeding occurred in two patients with cancer who
received fondaparinux (1.8 percent) and in three
patients with cancer who received unfractionated
heparin (2.3 percent). The incidences of recurrent
venous thromboembolism and major bleeding ac-
cording to body weight are shown in Table 4.
In the fondaparinux group, thrombocytopenia
occurred in 10 patients (0.9 percent), 1 of whom had
associated thromboembolism (myocardial infarc-
tion) and 1 of whom had major bleeding. Neither of
these patients had antiplatelet antibodies. In the un-
fractionated-heparin group, thrombocytopenia oc-
curred in 13 patients (1.2 percent). Two of these 13
patients had recurrent pulmonary embolism with-
out antiplatelet antibodies.
In this clinical trial of initial antithrombotic therapy
for acute symptomatic pulmonary embolism, thera-
py with fondaparinux, a selective inhibitor of factor
Xa, was not inferior to therapy with unfractionated
heparin. The two therapies were associated with a
similar incidence of adverse effects.
Optimal administration of intravenous unfrac-
tionated heparin requires reliable, frequent, and
timely blood sampling and laboratory testing with
reporting of the activated partial-thromboplastin
time to a clinician, who then adjusts the dosage as
needed. The minimal duration of treatment is five
to seven days.
 
4
 
 Deviations in clinical practice from
these complex, resource-intensive requirements are
well documented, and abandoning heparin for an
equally safe and effective but simpler therapy could
be considered advantageous.
 
19
 
In our study, care was taken to recruit a repre-
sentative sample of patients with pulmonary embo-
lism. The demographic features, range of risk fac-
tors, and spectrum of disease severity at enrollment
and the observed rates of recurrent and fatal venous
thromboembolic events were consistent with those
reported in previous investigations. Hence, our find-
ings regarding the efficacy and safety of fondapa-
rinux apply to a broad range of patients with hemo-
dynamically stable pulmonary embolism and have
the potential to simplify care.
Some methodologic aspects of this open-label
trial require comment. The procedures used to min-
imize bias included strict requirements to verify the
qualifying pulmonary embolism and any suspect-
ed recurrent venous thromboembolic or bleeding
events, as well as randomization at a central loca-
tion, nearly complete follow-up, and masked adju-
dication of each suspected outcome event. Success
at minimizing bias due to unmasked treatment as-
signment is supported by our finding that the diag-
nostic procedures at enrollment and at the time of
recurrence were similar and that the incidences of a
workup for and confirmation of suspected recur-
rence and bleeding in the two groups were similar.
Three considerations dictated the choice of un-
fractionated heparin rather than a low-molecular-
weight heparin as the comparator drug. Unfraction-
discussion
 
Table 3. Clinical Outcomes during the Study Period.
Population Fondaparinux
Unfractionated
Heparin
All patients randomly assigned to a study group
 
No. of patients 1103 1110
Recurrent venous thromboembolism 
— no. (%)
Initial treatment
Entire study
14 (1.3)
42 (3.8)
19 (1.7)
56 (5.0)
Type of recurrence — no.
Fatal pulmonary embolism
Nonfatal pulmonary embolism
Deep-vein thrombosis only
16
14
12
15
24
17
 
Patients as treated
 
No. of patients 1092 1092
Major bleeding — no. (%)
Initial treatment
Entire study
14 (1.3)
22 (2.0)
12 (1.1)
26 (2.4)
Clinically relevant nonmajor bleeding only 
— no. (%)
Initial treatment
Entire study
35 (3.2)
62 (5.7)
57 (5.2)
92 (8.4)
Death — no. (%)
Initial treatment
Entire study
9 (0.8)
57 (5.2)
12 (1.1)
48 (4.4)
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ated heparin is the parenteral anticoagulant most
widely used for initial therapy for pulmonary em-
bolism, direct evidence that low-molecular-weight
heparins are as effective as unfractionated heparin
remains limited, and many clinicians prefer unfrac-
tionated heparin for this indication.
 
3
 
Care was taken to apply the highest treatment
standards to the use of unfractionated heparin and
vitamin K antagonists. Among the necessary stand-
ards were those pertaining to the starting dose and
dose adjustments, the minimal duration of treat-
ment, and the target INR to be reached before hep-
arin or fondaparinux could be stopped. Our results
indicate that these standards were achieved in al-
most all the patients.
The objective of the study was to determine
whether fondaparinux is noninferior to unfraction-
ated heparin in preventing a recurrence of venous
thromboembolism. The predefined margin for the
comparison was consistent with those used in pre-
vious trials. Whereas an upper 95 percent confi-
dence interval of up to 3.5 percent in favor of un-
fractionated heparin was allowed, the upper limit
of 0.5 percent found in the study firmly establishes
the noninferiority of fondaparinux.
Even though patients in the fondaparinux group
were not prospectively assigned to early discharge,
early discharge was permitted and occurred in 14.5
percent of them, who continued to receive fonda-
parinux on an outpatient basis. In this subgroup of
158 patients, the rate of recurrence was low (3.2 per-
cent), and no major bleeding occurred.
In the past, bleeding complications were classi-
fied as major or minor. Whereas the definition of
major bleeding in the setting of treatment for venous
thromboembolism is generally well accepted and
has been shown to be reliable,
 
20
 
 “minor” bleeding
may range from bleeding that is clinically significant
but does not quite meet the criteria for major bleed-
ing to much less severe episodes such as gingival
bleeding. To overcome this limitation, we intro-
duced and defined a category of “clinically relevant
nonmajor bleeding” to identify and assess the rele-
vant hemorrhagic complications associated with
antithrombotic therapy more accurately.
In conclusion, once-daily, unmonitored, subcu-
taneous administration of fondaparinux was not in-
ferior to the use of unfractionated heparin for the
initial treatment of hemodynamically stable pulmo-
nary embolism, and rates of adverse events were
similar with the two therapies. In our opinion, be-
cause of its simplicity, once-daily subcutaneous
administration of fondaparinux without anticoagu-
lation monitoring could replace intravenous admin-
istration of unfractionated heparin in most patients
with this disorder.
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wa; C. Licksai, Windsor; M. Mant, Edmonton; Y. Pesant, Saint-Jérome; D. Rolf, Kelowna; H. Stelzer, Peterborough; A.G.G. Turpie, Hamil-
 
Table 4. Rates of Recurrent Venous Thromboembolism and Major Bleeding, According to Body Weight.
Study Group
Recurrent Venous Thromboembolism
during the 3-Month Study Period
Major Bleeding during the Initial
Treatment Period
 
<50 kg 50–100 kg >100 kg <50 kg 50–100 kg >100 kg
 
number/total number (percent)
 
Fondaparinux 5/22 (22.7) 32/945 (3.4) 5/132 (3.8) 0/21 (0) 13/939 (1.4) 1/130 (0.8)
Unfractionated heparin 4/25 (16) 41/948 (4.3) 11/136 (8.1) 1/25 (4) 10/932 (1.1) 1/134 (0.7)
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ton; T. Wong, Winnipeg. 
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Italy
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tients, 13 centers): G. Agnelli, Perugia; G.M. Ambrosio, Venezia; F. Ghirarduzzi, Reggio Emilia; C. Giuntini, Pisa; D. Imberti, Piacenza;
A. D’Angelo, I. Martinelli, F. Porro, Milan; V. Pengo, P. Prandoni, Padova; M. Barone, Pavia; R. Poggio, Genoa; G. Scannapieco, Treviso; P.F.
Tropeano, Pordenone. 
 
Israel
 
 (28 patients, 5 centers): B. Brenner, Haifa; M.H. Ellis, Kfar-Saba; G. Lugassy, Ashkelon; E. Naparstek (A. El-
dor), Tel Aviv; D. Varon, Tel-Hashomer. 
 
Poland
 
 (91 patients, 8 centers): J. Kloczko, Bialystok; P. Kolodziej, Siedlce; J. Lewczuk, Wroclaw;
J. Michalak, Lublin; L. Polonski, Zabre; P. Pruszczyk, W. Tomkowski, Warsaw; K. Zawilska, Poznan. 
 
Spain
 
 (32 patients, 5 centers): R. Barba,
Alcorcón; J. Lasierra, Logroño; M. Monreal-Bosch, Barcelona; R. Otero, Seville; F. Uresandi, Baracaldo. 
 
Sweden
 
 (51 patients, 6 centers):
J. Aagesen, Jönköping; H. Eriksson, L. Lapidus, Göteborg; Gerd Lärfars, B. Leijd, S. Schulman, Stockholm. 
 
Switzerland
 
 (60 patients, 6 cen-
ters): E. Bächli, Zurich; P.A. Cerny, Lugano; C. Henzen, Luzern; H. Kohler, Bern; G. Noseda, Mendrisio; J. Schifferli, Basel. 
 
The Netherlands
 
(243 patients, 13 centers): J.D. Banga, Utrecht; E. ten Berge, Hengelo; D.H. Biesma, Nieuwegein; T. Haitjema, Alkmaar; C. van de Heul,
Nieuwegein; D. Brandjes, M.M.W. Koopman, M. ten Wolde, P.E. Postmus, Amsterdam; T. Koster, Gouda; M. van Marwijk-Kooy, Zwolle;
J. van der Meer, Groningen; P.J. Stijnen, Breda; J. Creemers, Eindhoven. 
 
United Kingdom
 
 (29 patients, 5 centers): D. Bevan, A.T. Cohen,
P. Dillworth, P. Shah, London. 
 
United States
 
 (479 patients, 69 centers): C.L.V. Anderson, Bay Pines, Fla.; J. Ansell, Boston; W.C. Bazemore,
Asheville, N.C.; D.E. Bechard, Richmond, Va.; D. Bloomfield, Staten Island, N.Y.; W.C. Botnick, Vidalia, Ga.; W.R. Breitweiser, Grand Forks,
N.D.; D.E. Buffington, Tampa, Fla.; W. Caras, Tacoma, Wash.; S.N. Chohan, Oklahoma City; R. Dobbin Chow, Baltimore; M. Cipolle, Allen-
town, Pa.; G.L. Colice, Washington, D.C.; P.C. Comp, Oklahoma City; J. Cooper, Alexandria, Va.; B.L. Davidson, Seattle; S.R. Deitcher,
Cleveland; A. Dunn, New York; S. Durica, Norman, Okla.; C.G. Elliott, Salt Lake City; W. Farra, Southfield, Mich.; C.M. Fogarty, Spartan-
burg, S.C.; C.W. Francis, Rochester, N.Y.; E.L. Franks, Kansas City, Mo.; L.M. Gilliard, Orlando, Fla.; J.E. Godwin, Maywood, Ill.; J. Gossage,
Augusta, Ga.; W. Greth, R. Griffin, West Reading, Pa.; J. Guzman, Detroit; K. Hassell, Denver; D.E. Heiselman, Akron, Ohio; D. Bratzler,
D. Hitzeman, Tulsa, Okla.; T.M. Hyers, St. Louis; S. Idell, Tyler, Tex.; J. Ilowite, Mineola, N.Y.; D. Katula, Columbus, Ohio; L.W. Kendrick,
North Little Rock, Ark.; D. Kereiakes, Cincinnati; H. Khouli, New York; S. Knoper, Tucson, Ariz.; D.P. Lawlor, Olathe, Kans.; R.G. Lerner,
Valhalla, N.Y.; D.G. Lorch, Brandon, Fla.; T.A. Morris, San Diego, Calif.; A. O’Brien-Ladner, Kansas City, Kans.; D. Olson, Toledo, Ohio;
D. Ost, Manhasset, N.Y.; V. Patel, Richmond, Va.; S. Rathbun, Oklahoma City; J.R. Rehm, Fredericksburg, Va.; L. Rice, Houston; F. Roberts,
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